sur Pentixapharm Holding AG (ETR:PTP)
Pentixapharm Holding AG: Q3 Outlook and Developments
Pentixapharm Holding AG recently reported on its Q3 updates, setting the stage for key developments in 2027. The Q3 update supports a 'BUY' recommendation ahead of the PANDA trial's initiation. Regulatory steps have progressed with FDA approval and ethics clearance in October, ensuring readiness for patient enrolment by Q1 2027.
Commercial partnerships are anticipated by mid-2027, offering validation for PentixaFor's market potential. A partnership would enhance infrastructure support and potentially reduce funding dependency. Meanwhile, PENTHERA offers a promising therapeutic approach coupled with PentixaFor's imaging technology for AML and multiple myeloma treatment.
Pentixapharm operates with a lower cost base, reporting an EBITDA loss of €2.4m in Q3. With convertible bonds extended and reduced personnel expenses, funding appears secure until 2028. The core opportunity in oncology remains robust, with research reaffirming a target price of €7.20 per share.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Pentixapharm Holding AG